Brasil | Artículos de revistas

Detection of hepatitis C virus resistant mutants in the era of direct acting antivirals

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.date.accessioned2022-04-29T12:27:47Z
dc.date.accessioned2022-12-20T03:27:09Z
dc.date.available2022-04-29T12:27:47Z
dc.date.available2022-12-20T03:27:09Z
dc.date.created2022-04-29T12:27:47Z
dc.date.issued2014-01-01
dc.identifierAmerican Journal of Infectious Diseases, v. 10, n. 4, p. 182-186, 2014.
dc.identifier1553-6203
dc.identifierhttp://hdl.handle.net/11449/232354
dc.identifier10.3844/ajidsp.2014.182.186
dc.identifier2-s2.0-84920986572
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5412490
dc.description.abstractHepatitis C Virus (HCV) infects millions of people and represents an important public health problem in different regions of the world. Drug resistance is a major challenge for HCV-infection related control. Importantly, the arrival of a plethora of novel, more powerful drugs has revolutionized the field of HCV treatment. Here, we discuss the relevance of identification of HCV resistant mutants from a clinical standpoint. The advantage and limitations of molecular testing in clinical setting is presented.
dc.languageeng
dc.relationAmerican Journal of Infectious Diseases
dc.sourceScopus
dc.subjectDirect acting-antiviral
dc.subjectHepatitis C virus
dc.subjectResistant mutants
dc.subjectTherapy
dc.titleDetection of hepatitis C virus resistant mutants in the era of direct acting antivirals
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución